Physician profile
Mauricio Velez
NPI 1780629253
$6,403.89
in general payments reported to CMS, 2019-2025
20 companies · $635 in 2025
The $635 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,578 · 2020: $1,011 · 2021: $1,194 · 2022: $1,065 · 2023: $580 · 2024: $340 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,556.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,181.40 | 2019-2025 | Cardiomems |
| Abiomed | $1,584.77 | 2019-2024 | Impella |
| Novartis Pharmaceuticals Corporation | $846.33 | 2019-2024 | Leqvio |
| Biosense Webster, INC. | $383.31 | 2025 | Carto 3 |
| Edwards Lifesciences Corporation | $262.39 | 2020 | |
| Boston Scientific Corporation | $205.72 | 2020-2023 | Watchman Access System |
| Medtronic, INC. | $175.45 | 2023-2025 | Micra, Mycarelink |
| Impulse Dynamics (USA) INC. | $170.78 | 2021 | |
| Cardiva Medical, INC. | $114.92 | 2021-2022 | |
| Biotronik INC. | $107.73 | 2019 | |
| Medtronic Vascular, INC. | $100.00 | 2019 | |
| Bridgebio Pharma, INC. | $61.67 | 2025 | Attruby |
| Janssen Pharmaceuticals, INC | $54.51 | 2022 | |
| Pfizer INC. | $38.48 | 2021-2022 | |
| Tetraphase Pharmaceuticals, INC. | $30.20 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $27.96 | 2024 | Onpattro |
| E.R. Squibb & Sons, L.L.C. | $20.00 | 2022 | |
| Scpharmaceuticals INC. | $19.17 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $19.10 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mauricio Velez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.